活性重组蛋白 Recombinant Human LILRB1/ILT-2/CD85j Protein　重组蛋白

种属

Human

表达宿主

HEK293 cells

描述

Recombinant Human LILRB1/ILT-2/CD85j Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gly24-His458) of Human LILRB1 (Accession #NP_006660.4) fused with an 6×His tag at the C-terminus.

标签

C-His

纯度

> 95% by SDS-PAGE.

内毒素

< 0.1 EU/μg of the protein by LAL method.

制剂

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

储存

Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。

复溶

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。

研究方向

LILRB1 结合 MHC I 类，还含有基于免疫受体酪氨酸的抑制基序，参与细胞内抑制信号转导，这使它们成为 MHC I 类介导的吞噬作用抑制的有力候选者。
LILRB1 和 PD1 在 CD8+ TEM 和 TEMRA 亚群中显示出不重叠的表达模式，并且阻断这两种途径可协同增强 CD8+ T 细胞功能。LILRB1 由 CD8+ TEMRA 子集高度表达，这是 BiTE 分子诱导毒性最有效的群体。表达 LILRB1 的 CD8+ T 细胞浸润实体瘤。LILRB1 阻断可增加体外 CD8+ T 细胞的溶细胞活性。

背景信息

CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family.CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

基因ID

10859

Swiss Prot

Q8NHL6

别名

LILRB1;CD85J;ILT-2;ILT2;LIR-1;LIR1;MIR-7;MIR7;PIR-B;PIRB